Ryan Savitz serves as Executive at Dianthus Therapeutics, Inc. /DE/, where they oversee executive responsibilities. Since joining the company, Ryan Savitz has executed 5 insider transactions totaling $1.6M, demonstrating a bearish approach to their equity position. Their most recent transaction on Feb 3, 2026 involved receiving (via award) 150,000 shares valued at $0.
Ryan Savitz currently holds 150,000 shares of Dianthus Therapeutics, Inc. /DE/ (DNTH), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Ryan Savitz has been a net seller of DNTH stock. They have purchased $0 and sold $1.6M worth of shares.
Ryan Savitz's most recent insider trade was on Feb 3, 2026, when they sold 150,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $8.44 |
| Discretionary |
| Dec 4, 2025 | DNTH | $903.6K | Sale | 20,000 | $45.18 | Discretionary |
| Sep 9, 2025 | DNTH | $168.8K | Option Exercise | 20,000 | $8.44 | Discretionary |
| Sep 9, 2025 | DNTH | $700.0K | Sale | 20,000 | $35.00 | Discretionary |